101 results
8-K
EX-99.1
INVA
Innoviva Inc
25 Apr 13
Regulation FD Disclosure
12:00am
with Merck and partnerships with Alfa Wassermann, Clinigen and R-Pharm Led by experienced leadership team Maintain current integrated R&D capabilities … Efficient corporate structure: GSK pays all commercialization and R&D expenses related to partnered respiratory programs RELVAR™ or BREO™ ELLIPTA™ (FF/VI
8-K
EX-99.1
INVA
Innoviva Inc
14 Sep 22
Regulation FD Disclosure
5:22pm
healthcare expertise across governance, strategy, medicine / science, R&D, finance, and operations 2 High-potential, robust operating platform … to healthcare Entasis / La Jolla combination creates an integrated therapeutics platform with strong R&D engine and superior hospital-focused
8-K
EX-99.1
INVA
Innoviva Inc
21 Apr 14
Theravance Closes Private Placement of $450 Million of 9% Non-Recourse Notes Supporting Strategic Separation Process
12:00am
in April 2013 that it would separate late-stage partnered respiratory assets from its biopharmaceutical research and development (R&D) operations and create … two companies, Theravance, Inc. (the royalty management company) and Theravance Biopharma (the R&D company). This strategic separation is expected
8-K
EX-99.13
INVA
Innoviva Inc
4 Sep 12
Other Events
12:00am
when administered in the morning or evening
Rodger Kempsford(1), Amanda Oliver(2), Lee Tombs(3), Joanne Bal(4)
GlaxoSmithKline R&D Respiratory … Medicines Development Centre (1)Stevenage, UK and (2)Uxbridge, UK; (3)Synergy, Slough, UK; (4)GlaxoSmithKline R&D Clinical Pharmacology Science & Study
8-K
EX-99
INVA
Innoviva Inc
6 Feb 14
Results of Operations and Financial Condition
12:00am
(R&D)
Research and development expense for the full year of 2013 was $125.2 million compared with $117.9 million for the full year of 2012 … . The increase in the full year of 2013 was primarily due to higher external R&D costs and employee-related expenses. External R&D costs for the full year of 2013
8-K
EX-99.1
v5jgp4b
7 Apr 22
Regulation FD Disclosure
5:09pm
8-K
EX-99
ojdar
20 May 11
Other Events
12:00am
8-K
EX-99
hr1n8ukgysty1g0
15 Sep 11
Other Events
12:00am
SC TO-C
EX-99.2
xb1uiyloybre zo
23 May 22
Information about tender offer
8:54pm
8-K
EX-99.1
vvm yxgqs2jvajg
13 May 24
Corporate Presentation May 2024
9:27am
8-K
EX-99.1
o7yysg60c
24 May 23
Corporate Presentation May 2023
5:18pm
8-K
EX-99
g9co16l
20 Feb 07
Other Events
12:00am
8-K
EX-99
e9u0b83
8 Dec 06
Other Events
12:00am
8-K
EX-99.1
gp7ppmmew07ci2wm
13 Dec 21
Corporate Presentation December 2021
4:39pm
8-K
EX-99
cqtgkq2
8 Nov 05
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99
9q6ck kv0
18 Jul 06
Entry into a Material Definitive Agreement
12:00am